208 related articles for article (PubMed ID: 11313395)
1. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL.
Nelson DJ; Mukherjee S; Bundell C; Fisher S; van Hagen D; Robinson B
J Immunol; 2001 May; 166(9):5557-66. PubMed ID: 11313395
[TBL] [Abstract][Full Text] [Related]
2. In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes.
Nelson D; Bundell C; Robinson B
J Immunol; 2000 Dec; 165(11):6123-32. PubMed ID: 11086045
[TBL] [Abstract][Full Text] [Related]
3. Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation.
Stumbles PA; Himbeck R; Frelinger JA; Collins EJ; Lake RA; Robinson BW
J Immunol; 2004 Nov; 173(10):5923-8. PubMed ID: 15528325
[TBL] [Abstract][Full Text] [Related]
4. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
[TBL] [Abstract][Full Text] [Related]
5. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.
Krishnan L; Sad S; Patel GB; Sprott GD
J Immunol; 2000 Nov; 165(9):5177-85. PubMed ID: 11046050
[TBL] [Abstract][Full Text] [Related]
6. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
[TBL] [Abstract][Full Text] [Related]
7. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo.
Prévost-Blondel A; Roth E; Rosenthal FM; Pircher H
J Immunol; 2000 Apr; 164(7):3645-51. PubMed ID: 10725721
[TBL] [Abstract][Full Text] [Related]
8. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity.
Hermans IF; Ritchie DS; Yang J; Roberts JM; Ronchese F
J Immunol; 2000 Mar; 164(6):3095-101. PubMed ID: 10706699
[TBL] [Abstract][Full Text] [Related]
9. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses.
Lu J; Higashimoto Y; Appella E; Celis E
J Immunol; 2004 Apr; 172(7):4575-82. PubMed ID: 15034075
[TBL] [Abstract][Full Text] [Related]
10. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
[TBL] [Abstract][Full Text] [Related]
11. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes.
Blohm U; Roth E; Brommer K; Dumrese T; Rosenthal FM; Pircher H
J Immunol; 2002 Nov; 169(10):5522-30. PubMed ID: 12421928
[TBL] [Abstract][Full Text] [Related]
12. Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction.
Boonman ZF; van Mierlo GJ; Fransen MF; Franken KL; Offringa R; Melief CJ; Jager MJ; Toes RE
J Immunol; 2004 Feb; 172(3):1567-74. PubMed ID: 14734736
[TBL] [Abstract][Full Text] [Related]
13. Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1.
Coles RM; Mueller SN; Heath WR; Carbone FR; Brooks AG
J Immunol; 2002 Jan; 168(2):834-8. PubMed ID: 11777979
[TBL] [Abstract][Full Text] [Related]
14. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses.
Vabulas RM; Pircher H; Lipford GB; Häcker H; Wagner H
J Immunol; 2000 Mar; 164(5):2372-8. PubMed ID: 10679072
[TBL] [Abstract][Full Text] [Related]
15. Reversal of CD8+ T cell ignorance and induction of anti-tumor immunity by peptide-pulsed APC.
Dalyot-Herman N; Bathe OF; Malek TR
J Immunol; 2000 Dec; 165(12):6731-7. PubMed ID: 11120791
[TBL] [Abstract][Full Text] [Related]
16. Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors.
Bundell CS; Jackaman C; Suhrbier A; Robinson BW; Nelson DJ
Cancer Immunol Immunother; 2006 Aug; 55(8):933-47. PubMed ID: 16283304
[TBL] [Abstract][Full Text] [Related]
17. In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen).
Goldberg J; Shrikant P; Mescher MF
J Immunol; 2003 Jan; 170(1):228-35. PubMed ID: 12496404
[TBL] [Abstract][Full Text] [Related]
18. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
20. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.
Lugade AA; Moran JP; Gerber SA; Rose RC; Frelinger JG; Lord EM
J Immunol; 2005 Jun; 174(12):7516-23. PubMed ID: 15944250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
